Spyre Therapeutics Inc SYRE.OQ SYRE.O is expected to show a rise in quarterly revenue when it reports results on February 28 (estimated) for the period ending December 31 2024
The Waltham Massachusetts-based company is expected to report revenue of $2.1 million, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Spyre Therapeutics Inc is for a loss of 99 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Spyre Therapeutics Inc is $65.00, above its last closing price of $20.65.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.80 | -0.82 | -1.36 | Missed | -65 |
Jun. 30 2024 | -1.02 | -0.95 | -0.86 | Beat | 9.5 |
Mar. 31 2024 | -1.18 | -1.17 | -1.20 | Missed | -2.9 |
Dec. 31 2023 | -0.52 | -0.78 | -4.05 | Missed | -416.4 |
Sep. 30 2023 | -0.68 | -0.84 | -9.34 | Missed | -1,005.3 |
Jun. 30 2023 | -4.50 | -4.50 | -41.50 | Missed | -822.2 |
Mar. 31 2023 | -4.75 | -4.50 | -5.00 | Missed | -11.1 |
Dec. 31 2022 | -5.04 | -5.00 | -4.50 | Beat | 10 |
This summary was machine generated February 26 at 21:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。